Christos Poulios
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christos Poulios has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- George Fountzilas
Aristotle University of Thessaloniki, Thessaloniki, Greece
60 shared publications - Dimitrios Pectasides
Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece
58 shared publications - Aileen I. Fernandez
Department of Pathology, Yale School of Medicine, New Haven, Connecticut
57 shared publications - Alexander Delides
2nd Otolaryngology Department, Attikon University Hospital, National and Kapodistrian University of Athens, 12462 Athens, Greece
57 shared publications - Amanda Psyrri
Medical Oncology Unit, 2nd Department of Internal Medicine, “ATTIKON” General Hospital of Athens, 12462 Athens, Greece
57 shared publications - Andromachi Kougioumtzopoulou
Department of Clinical Radiation Oncology, Medical School, National and Kapodistrian University of Athens, “Attikon” University Hospital, 12462 Haidari, Greece
57 shared publications
Latest Publications
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 2. Differentially expressed signatures in Responders relative to no-Responders. Response is based on physical examination, pathology or imaging. Responders had higher scores in Inflammatory Chemokines and Exhausted CD8 Signatures, as well as PD-1, Cytotoxicity and CD45. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 2. Differentially expressed signatures in Responders relative to no-Responders. Response is based on physical examination, pathology or imaging. Responders had higher scores in Inflammatory Chemokines and Exhausted CD8 Signatures, as well as PD-1, Cytotoxicity and CD45. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 1a. Representativeness of Study Participants SupplementaryTable 1b. Nanostring IO360 panel
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 1a. Representativeness of Study Participants SupplementaryTable 1b. Nanostring IO360 panel
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 6. Posttreatment CD163 (by QIF) increase in three patients with concurrent increase in the CD163 transcripts. Representative images from a patient’s tumor tissue sample showing pre and post treatment (Durvalumab-Olaparib Arm) CD163 expression. Nuclei (blue), Cytokeratin (green), CD163 (yellow) and CSF1R (red).
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 6. Posttreatment CD163 (by QIF) increase in three patients with concurrent increase in the CD163 transcripts. Representative images from a patient’s tumor tissue sample showing pre and post treatment (Durvalumab-Olaparib Arm) CD163 expression. Nuclei (blue), Cytokeratin (green), CD163 (yellow) and CSF1R (red).
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 2. Signature scores with significanlty changes pre- and post-Olaparib based treatment
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 2. Signature scores with significanlty changes pre- and post-Olaparib based treatment
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 5. Map showing the distribution of mutations per gene per tumor. Light and dark purple, green and orange indicate pre- and post-treatment samples for patients treated with cisplatin and olaparib, olaparib and durvalumab and olaparib only, respectively. Blues correspond to samples before and after second biopsy/surgery for patients who did not receive treatment.
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 5. Map showing the distribution of mutations per gene per tumor. Light and dark purple, green and orange indicate pre- and post-treatment samples for patients treated with cisplatin and olaparib, olaparib and durvalumab and olaparib only, respectively. Blues correspond to samples before and after second biopsy/surgery for patients who did not receive treatment.
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
TABLE 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Patient and tumor characteristics at baseline
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTABLE 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Patient and tumor characteristics at baseline
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 3. Genes with significanlty changes pre- and post-Olaparib based treatment
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Table 3. Genes with significanlty changes pre- and post-Olaparib based treatment
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Table 4a. Fold-change values for each signature between Response and No Response based on physical examination, pathology or imagingTable 4b. Fold-change values for significantly differentially expressed genes between Response and No Response based on physical examination, pathology or imaging
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Table 4a. Fold-change values for each signature between Response and No Response based on physical examination, pathology or imagingTable 4b. Fold-change values for significantly differentially expressed genes between Response and No Response based on physical examination, pathology or imaging
- Open Access
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
- 10 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.